Welcome!

News Feed Item

Blood-Brain Barrier Technologies and Global Markets

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Blood-Brain Barrier Technologies and Global Markets

http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html

This BCC Research report analyzes the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are also discussed. This report offers an outlook of the technology's potential that is on the verge of rapid increase.

Use this report to:
- Determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential over a five-year period from 2014
through 2019.
- Receive information about the key drivers and key challenges involved in BBB technologies.
- Receive information about the promising CNS drugs that are in the later stage of the development pipeline for potential use with BBB technology.
- Learn about key BBB technology patents.

Highlights
- The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
- Receptor mediated transport is the largest segment of the global BBB market and is projected to increase from about $38.7 million in 2014 to $456 million by 2019, with a CAGR of 63.8% for the period of 2014 to 2019.
- Carrier-mediated transport (CMT) is an emerging technology that is expected to reach $15.5 million by 2019.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
BCC Research's goal in conducting this study was to determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its
growth potential over a five-year period from 2014 through 2019. Our key objective was to present a comprehensive analysis of the current BBB technology and drug
development market and its future direction, with the aim to first define and classify that technology as it pertains to therapeutics in which the technology enables the
therapeutic to directly cross rather than bypass the BBB.

REASONS FOR DOING THIS STUDY
BBB technologies are poised to open up a vast untapped potential in the growing central nervous system therapeutic market, where today growth is limited by the
complexity of this layer in the brain that prevents the passage of many potentially useful molecules/compounds. This report offers an outlook of the technology's potential that is on the verge of rapid increase. Therapeutics make up the main area of investment related to this technology — and the main focus of this report. BCC Research has not yet examined the BBB, although the central nervous system has been a consistent focus. As such, this snapshot and study of trending and growth is unique.

SCOPE OF REPORT
The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development, in which a quality of the development
is enabling the crossing of the BBB, where passage was previously impossible often due to size. BCC Research analyzes each technology, determines its current market
status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

INTENDED AUDIENCE
In the report, the various BBB technologies are defined and given their history in medicine. The report also looks at the types and technology categories, major companies, impact on the pharmaceutical market, applications, current market values, growth potential and significant trends. This study will be of interest to the biotechnology and pharmaceutical industries and related life sciences, analytics, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug and imaging agent research and investors in all of the above.

METHODOLOGY
BCC Research presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of BBB technology in medicine as it relates primarily to drug discovery, development, and commercialization. Estimated values are based on actual aggregate sales for the years discussed. Overall, information is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.

INFORMATION SOURCES
BCC Research's analysis includes the review of more than 50 companies and information from financial and trade publications, as well as the US Food and Drug Administration (FDA). Pharmaceutical and biotechnology companies, as well as support companies, are also included.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 2
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
THROUGH 2019 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS) 7
EMERGING BBB TECHNOLOGY MARKET 10
KEY DRIVERS 12
KEY CHALLENGES 13
CHAPTER 3 OVERVIEW 15
MAJOR TRENDS 15
TODAY'S PHARMA MARKET 16
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION,
THROUGH 2017 ($ BILLIONS) 17
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND
2017 (PERCENT OF GLOBAL SALES) 18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO
THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS) 18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
REGION, 2019* ($ MILLIONS) 19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS) 20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%) 21
BIOLOGICS 22
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013 22
GENERICS SIGNAL NEED FOR INNOVATION 24
NEUROFOCUSING IN THE PHARMA INDUSTRY 24
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS) 24
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 (NUMBER OF UNITS COMMERCIALIZED) 26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION) 26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS) 27
EMERGING BBB TECHNOLOGY MARKET 28
BRIEF HISTORY OF BBB 29
BLOOD BRAIN BARRIER DEFINED 29
BBB COMPONENTS 30
Pericytes 30
Tight Junctions 31
Lipid Barrier 31
Enzymatic Barrier 31
Efflux Pumps 31
BBB ILLUSTRATED 31
FIGURE 7 PARTS OF THE BBB 31
MAIN AREAS OF THE BRAIN 32
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS 32
TREATING DISEASE AND THE BBB 34
MENINGITIS 34
MULTIPLE SCLEROSIS (MS) 34
ENCEPHALITIS 35
ALZHEIMER'S DISEASE (AD) 35
PARKINSON'S DISEASE (PD) 36
BBB TECHNOLOGY CLASSIFICATION 37
MOST COMMON BBB TECHNOLOGY 37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED 38
TRANSPORT CONSIDERATIONS 39
Bypassing the BBB 39
BBB TECHNOLOGY DETAILED 39
Chemical Transport Systems 40
Biological Carrier or Transport Systems 40
Physical Force (Energetic) Opening Through Sound Waves (Targeted
Ultrasound) 41
Enhancing Biological Transport System Techniques 42
FIGURE 9 METHODS OF CROSSING THE BBB 42
Nanoparticles and Liposomes 43
Nanoparticles 43
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY 44
Challenges with Nanoparticles 45
Liposomes 45
PATENTS AND INTELLECTUAL PROTECTION 47
TABLE 7 KEY BBB TECHNOLOGY PATENTS 48
ArmaGen's Patent Estate 50
Life After Patenting 53
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013 54
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE 54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS) 55
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY) 56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET) 56
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014
AND 2019 (NUMBER OF UNITS) 58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL
METHOD 59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING
DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET 61
Genzyme Innovates and Sells Technology to Pharmidex 61
DRUG DEVELOPMENT IN THE CNS 62
Multiple Models Must Be Used 62
BBB Is Its Own Site of Investigation 63
Understanding Interactions and Brain Areas as Distinct 64
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB
TECHNOLOGIES 64
What Values Are Best 66
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS 67
PROMISING RESEARCH 67
PROMISING CNS DRUGS THAT ARE LATER STAGE IN THE DEVELOPMENT
PIPELINE FOR POTENTIAL USE WITH BBB TECHNOLOGY 70
Brain Cancer 70
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019 71
Anxiety 74
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019 74
Dementia 75
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019 75
Parkinson's disease 77
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019 77
Depression 78
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019 78
Personality/Psychiatric Disorders (Schizophrenia/bipolar) 79
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019 80
Spinal Cord Injury 80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019 81
Addiction Disorders 81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019 81
Attention Deficit Hyperactivity Disorder (ADHD) 82
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019 82
Sleep Disorders 83
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019 83
CHAPTER 4 COMPANY PROFILES 86
ABLYNX 86
ADENIOS 87
ANGIOCHEM 87
ARMAGEN TECHNOLOGIES 89
BIOASIS TECHNOLOGIES 90
BRISTOL-MYERS SQUIBB 91
CAPSULUTION PHARMA 92
DAINIPPON SUMITOMO PHARMA 93
ELI LILLY AND COMPANY 93
EUTHYMICS BIOSCIENCE 94
FABRE-KRAMER PHARMACEUTICALS 95
FLOCEL 95
FORUM PHARMACEUTICALS 96
GENZYME 97
INSIGHTEC 97
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS) 98
ISIS INNOVATION 98
JANSSEN PHARMACEUTICA 99
H LUNDBECK 100
MEDGENESIS THERAPEUTIX (BIOVAIL LAB) 101
MEDIMMUNE 101
MEDINVENT 102
NANOMERICS 102
NEUROVIVE PHARMACEUTICAL 103
NEUREN PHARMACEUTICALS 103
NSGENE 104
OPTINOSE 106
OSSIANIX 106
OTSUKA AMERICA PHARMACEUTICAL 107
PROTHENA CORP 107
PROTHERAGEN 108
PFIZER 108
PHARMACO-CELL 109
PHARMIDEX 109
RAPTOR PHARMACEUTICAL 111
ROCHE 112
ROYALTY PHARMA 112
SHIRE 113
SANERON CCEL THERAPEUTICS 113
SOLVO BIOTECHNOLOGY 114
SOVICELL 115
TEVA PHARMACEUTICAL INDUSTRIES 115
TO-BBB TECHNOLOGIES 116
TTY BIOPHARM 117
UCB 118
VECT-HORUS 118
XENOPORT 119
XIGEN 120


LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
THROUGH 2019 ($ MILLIONS) 7
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH
2017 ($ BILLIONS) 17
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013 22
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 (NUMBER OF UNITS COMMERCIALIZED) 26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE
CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION) 26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS) 27
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY 44
TABLE 7 KEY BBB TECHNOLOGY PATENTS 48
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013 54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS) 55
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL
METHOD 59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING
DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET 61
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB
TECHNOLOGIES 64
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS 67
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019 71
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019 74
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019 75
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019 77
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019 78
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019 80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019 81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019 81
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019 82
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019 83


LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS) 7
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND
2017 (PERCENT OF GLOBAL SALES) 18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO
THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS) 18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION,
2019* ($ MILLIONS) 19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS) 20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%) 21
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS) 24
FIGURE 7 PARTS OF THE BBB 31
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS 32
FIGURE 9 METHODS OF CROSSING THE BBB 42
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY) 56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET) 56
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58



To order this report: Blood-Brain Barrier Technologies and Global Markets
http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
From wearable activity trackers to fantasy e-sports, data and technology are transforming the way athletes train for the game and fans engage with their teams. In his session at @ThingsExpo, will present key data findings from leading sports organizations San Francisco 49ers, Orlando Magic NBA team. By utilizing data analytics these sports orgs have recognized new revenue streams, doubled its fan base and streamlined costs at its stadiums. John Paul is the CEO and Founder of VenueNext. Prior ...
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Businesses are struggling to manage the information flow and interactions between all of these new devices and things jumping on their network, and the apps and IT systems they control. The data businesses gather is only helpful if they can do something with it. In his session at @ThingsExpo, Chris Witeck, Principal Technology Strategist at Citrix, will discuss how different the impact of IoT will be for large businesses, expanding how IoT will allow large organizations to make their legacy ap...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Apache Hadoop is a key technology for gaining business insights from your Big Data, but the penetration into enterprises is shockingly low. In fact, Apache Hadoop and Big Data proponents recognize that this technology has not yet achieved its game-changing business potential. In his session at 19th Cloud Expo, John Mertic, director of program management for ODPi at The Linux Foundation, will explain why this is, how we can work together as an open data community to increase adoption, and the i...
"We have several customers now running private clouds. They're not as large as they should be but it's getting there. The adoption challenge has been pretty simple. Look at the world today of virtualization vs cloud," stated Nara Rajagopalan, CEO of Accelerite, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
What does it look like when you have access to cloud infrastructure and platform under the same roof? Let’s talk about the different layers of Technology as a Service: who cares, what runs where, and how does it all fit together. In his session at 18th Cloud Expo, Phil Jackson, Lead Technology Evangelist at SoftLayer, an IBM company, spoke about the picture being painted by IBM Cloud and how the tools being crafted can help fill the gaps in your IT infrastructure.
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of (at least) three separate application components: the software embedded in the device, the back-end service, and the mobile application for the end user’s controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/target –...
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...